Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 167

Showing 1-25 of 167 citing articles:

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
John R. Ussher, Daniel J. Drucker
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 463-474
Closed Access | Times Cited: 211
COPD and multimorbidity: recognising and addressing a syndemic occurrence
Leonardo M. Fabbri, Bartolomé R. Celli, Àlvar Agustí, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 11, pp. 1020-1034
Open Access | Times Cited: 84
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction
Matteo Pagnesi, Marco Metra, Alain Cohen‐Solal, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 22, pp. 2131-2144
Open Access | Times Cited: 47
Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management
Annabelle M. Warren, Mathis Grossmann, Mirjam Christ‐Crain, et al.
Endocrine Reviews (2023) Vol. 44, Iss. 5, pp. 819-861
Open Access | Times Cited: 46
Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes
Julie M. Paik, Helen Tesfaye, Gary C. Curhan, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 3, pp. 265-265
Closed Access | Times Cited: 23
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes
Pasquale Mone, Angela Lombardi, Urna Kansakar, et al.
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 384, Iss. 1, pp. 116-122
Open Access | Times Cited: 66
Kidney-Protective Effects of SGLT2 Inhibitors
Biff F. Palmer, Deborah J. Clegg
Clinical Journal of the American Society of Nephrology (2022) Vol. 18, Iss. 2, pp. 279-289
Open Access | Times Cited: 56
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Yafei Xie, Yujie Wei, Dan Li, et al.
Journal of Cardiovascular Pharmacology (2023) Vol. 81, Iss. 1, pp. 4-14
Closed Access | Times Cited: 32
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management
Naseema Gangat, Natasha Szuber, Ayalew Tefferi
American Journal of Hematology (2023) Vol. 98, Iss. 6, pp. 965-981
Open Access | Times Cited: 29
IgA nephropathy in adults—treatment standard
Patrick J. Gleeson, Michelle M. O’Shaughnessy, Jonathan Barratt
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 11, pp. 2464-2473
Open Access | Times Cited: 29
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
Sara Piccini, Giuseppe Favacchio, Cristina Panico, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Physics-informed neural networks (PINNs) for 4D hemodynamics prediction: An investigation of optimal framework based on vascular morphology
Xuelan Zhang, Baoyan Mao, Yue Che, et al.
Computers in Biology and Medicine (2023) Vol. 164, pp. 107287-107287
Open Access | Times Cited: 24
Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data
Robert A. Kloner, Eric J. Stanek, Christopher L. Crowe, et al.
The Journal of Sexual Medicine (2023) Vol. 20, Iss. 1, pp. 38-48
Open Access | Times Cited: 23
Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials
Bernardo Frison Spiazzi, Rafaella A. Naibo, Laura Fink Wayerbacher, et al.
Diabetes Research and Clinical Practice (2023) Vol. 198, pp. 110621-110621
Closed Access | Times Cited: 23
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events
Buena Aziri, Edin Begić, Slobodan Јаnkovic, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 3, pp. 1499-1530
Open Access | Times Cited: 23
Role and molecular mechanisms of SGLT2 inhibitors in pathological cardiac remodeling (Review)
B K Chen, Jing Guo, Ye Hongmei, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 5
Open Access | Times Cited: 9
Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial
Duk‐Hyun Kang, Sung‐Ji Park, Sung‐Hee Shin, et al.
Circulation (2024) Vol. 149, Iss. 24, pp. 1865-1874
Closed Access | Times Cited: 9
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes
P. Natale, David J. Tunnicliffe, Tadashi Toyama, et al.
Cochrane library (2024) Vol. 2024, Iss. 5
Closed Access | Times Cited: 9
Sodium-Glucose Cotransporter-2 Inhibitors and Nephritis Among Patients With Systemic Lupus Erythematosus
Fu‐Shun Yen, Shiow‐Ing Wang, Chih-Cheng Hsu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 6, pp. e2416578-e2416578
Open Access | Times Cited: 9
Edema formation in congestive heart failure and the underlying mechanisms
Zaid Abassi, Emad E. Khoury, Tony Karram, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 35
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Huijing Wang, Ting Li, Fangfang Sun, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002686-e002686
Open Access | Times Cited: 29
SGLT-2 Inhibitors and the Inflammasome: What’s Next in the 21st Century?
Dimitris Kounatidis, Natalia G. Vallianou, Angelos Evangelopoulos, et al.
Nutrients (2023) Vol. 15, Iss. 10, pp. 2294-2294
Open Access | Times Cited: 21
Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis
Benjamin Steinhorn, Jeanine P. Wiener-Kronish
British Journal of Anaesthesia (2023) Vol. 131, Iss. 4, pp. 682-686
Closed Access | Times Cited: 18
Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of randomized controlled trials
Ernesto Maddaloni, Ilaria Cavallari, Ylenia La Porta, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 5, pp. 1341-1350
Closed Access | Times Cited: 17
Page 1 - Next Page

Scroll to top